

Transcatheter Pulmonary Valve Implantation

Policy # 00576

Original Effective Date: 10/18/2017

Current Effective Date: 10/01/2026

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Investigational or experimental services are not covered. This includes any drug, device, procedure, or service provided under the investigational arm of a clinical trial or clinical study. These services are excluded from coverage under benefits.

Note: Transcatheter Aortic Valve Implantation for Aortic Stenosis is addressed separately in medical policy 00406.

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider transcatheter pulmonary valve implantation to be **eligible for coverage**** when the following criteria are met:

- Request is for a Food and Drug Administration (FDA)-approved valve; **AND**
- For individuals with congenital heart disease and current right ventricular outflow tract obstruction (RVOT) or regurgitation; **AND**
- In **ANY** of the following situations:
 - Individuals with right ventricle-to-pulmonary artery conduit with or without bioprosthetic valve with at least moderate pulmonic regurgitation; **OR**
 - Individuals with native or patched RVOT with at least moderate pulmonic regurgitation; **OR**
 - Individuals with right ventricle-to-pulmonary artery conduit with or without bioprosthetic valve with pulmonic stenosis (mean RVOT gradient at least 35 mm Hg); **OR**
 - Individuals with native or patched RVOT with pulmonic stenosis (mean RVOT gradient at least 35 mm Hg).

When Services Are Considered Not Medically Necessary

Based on review of available data, the Company considers transcatheter pulmonary valve implantation for all other indications and when coverage criteria are not met to be **not medically necessary.****

Policy # 00576

Original Effective Date: 10/18/2017

Current Effective Date: 10/01/2026

Background/Overview

Congenital Heart Disease

Congenital heart disease, including tetralogy of Fallot, pulmonary atresia, and transposition of the great arteries, is generally treated by surgical repair at an early age. This involves reconstruction of the right ventricular outflow tract (RVOT) and pulmonary valve using a surgical homograft or a bovine-derived valve conduit. These repairs are prone to development of pulmonary stenosis or regurgitation over long periods of follow-up. Individuals living with congenital heart disease also face disparities in social determinants of health and the inability to obtain quality lifelong care for their condition which can contribute to inequities in morbidity and mortality.

Because individuals with surgically corrected congenital heart disease repair are living into adulthood, RVOT dysfunction following initial repair has become more common. Calcification of the RVOT conduit can lead to pulmonary stenosis, while aneurysmal dilatation can result in pulmonary regurgitation. RVOT dysfunction can lead to decreased exercise tolerance, potentially fatal arrhythmias, and/or irreversible right ventricular dysfunction.

Treatment

Treatment options for pulmonary stenosis are open surgery with valve replacement, balloon dilatation, or percutaneous stenting.² The established interventions for pulmonary regurgitation are primarily surgical, either reconstruction of the RVOT conduit or replacement of the pulmonary valve. The optimal timing of these interventions is not well understood.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

Devices for transcatheter pulmonary valve implantation were initially cleared from marketing by the U.S. FDA through the humanitarian device exemption (HDE) process or used off-label until approved by FDA through the premarket approval (PMA) (see Table 1).

Table 1. Regulatory Status of Transcatheter Pulmonary Valve Implantation Devices

Device	Manufacturer	Date Approved	PMA No.	Indications
Melody [®] † Transcatheter Pulmonary Valve (TPV)	Medtronic	Jan 2010	H080002 (HDE)	Pulmonary valve replacement for pediatric and adult patients with a dysfunctional, noncompliant RVOT conduit
Melody [®] † TPV	Medtronic	Jan 2015	P140017	Pulmonary valve replacement for pediatric and adult patients with a dysfunctional, noncompliant RVOT conduit

Transcatheter Pulmonary Valve Implantation

Policy # 00576

Original Effective Date: 10/18/2017

Current Effective Date: 10/01/2026

Melody [®] TPV	Medtronic	Feb 2017	P140017/S005	Valve-in-valve for patients with a dysfunctional surgical bioprosthetic pulmonary valve
SAPIEN XT [™] Transcatheter Heart Valve (pulmonic)	Edwards Lifesciences	Feb 2016	P130009/S037	Pulmonary valve replacement for pediatric and adult patients with a dysfunctional, noncompliant RVOT conduit
SAPIEN 3 [™] Transcatheter Heart Valve System with Edwards Commander Delivery System	Edwards Lifesciences	Mar 2020	P200015	Pulmonary valve replacement for Dysfunctional RVOT conduit or surgical bioprosthetic valve in the pulmonic position
SAPIEN 3 [™] Transcatheter Pulmonary Valve System with Alterra Adaptive Presept	Edwards Lifesciences	Dec 2021	P200015	Pulmonary valve replacement for pediatric and adult patients with severe pulmonary regurgitation as measured by echocardiography who have a native or surgically-repaired right ventricular outflow tract
Harmony [™] TPV	Medtronic	Mar 2021	P200046	Pulmonary valve for pediatric and adult patients with severe pulmonary regurgitation

HDE: humanitarian device exemption; PMA: premarket approval; RVOT: right ventricular outflow tract.

In January 2010, the Melody[®] TPV and the Ensemble[®] Transcatheter Valve Delivery System (Medtronic) were approved by FDA under the HDE program for use as an adjunct to surgery in the management of pediatric and adult patients with the following clinical conditions:

- Existence of a full (circumferential) RVOT conduit that is 16 mm or greater in diameter when originally implanted, and
- Dysfunctional RVOT conduits with clinical indication for intervention, and either:
 - regurgitation: moderate-to-severe regurgitation, or
 - stenosis: mean RVOT gradient ≥ 35 mm Hg.

On January 27, 2015, approval of the Melody system was amended to a PMA because FDA determined that the device represented a breakthrough technology. The PMA was based, in part, on 2 prospective clinical studies, the Melody TPV Long-term Follow-up Post Approval Study and the Melody TPV New Enrollment Post Approval Study.

Transcatheter Pulmonary Valve Implantation

Policy # 00576

Original Effective Date: 10/18/2017

Current Effective Date: 10/01/2026

On February 24, 2017, approval of the Melody system was expanded to include patients with a dysfunctional surgical bioprosthetic valve (valve-in-valve).

The Edwards SAPIEN XT^{TM†} Transcatheter Heart Valve (Pulmonic) (Edwards Lifesciences) was approved by FDA in 2016 "for use in pediatric and adult patients with a dysfunctional, noncompliant Right Ventricular Outflow Tract (RVOT) conduit with a clinical indication for intervention and:

- pulmonary regurgitation $\geq$ moderate and/or
- mean RVOT gradient $\geq$ 35 mmHg."

The approval for the pulmonic valve indication is a supplement to the 2014 PMA for use of the Edwards SAPIEN XT Transcatheter Heart Valve System for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis and who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (ie, Society of Thoracic Surgeons operative risk score $\geq$ 8% or at a $\geq$ 15% risk of mortality at 30 days).

The Edwards SAPIEN 3 Transcatheter Heart Valve System with Edwards Commander Delivery System (Edwards Lifesciences) was approved by the FDA in 2020 for "the management of pediatric and adult patients who have a clinical indication for intervention on a dysfunctional RVOT conduit or surgical bioprosthetic valve in the pulmonic position with $\geq$ to moderate regurgitation and/or a mean RVOT gradient of $\geq$ to 35 mmHg". The Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestent was approved by the FDA in 2021 for "management of pediatric and adult patients with severe pulmonary regurgitation as measured by echocardiography who have a native or surgically-repaired right ventricular outflow tract and are clinically indicated for pulmonary valve replacement."

The Harmony^{TM‡} Transcatheter Pulmonary Valve (Medtronic) received breakthrough technology status in 2019 and PMA in 2021. This device is indicated "for use in pediatric and adult patients with severe pulmonary regurgitation (determined by echocardiography and/or pulmonary regurgitant fraction $\geq$ 30% by cardiac magnetic resonance imaging) who have a native or surgically-repaired right ventricular outflow tract and are clinically indicated for surgical pulmonary valve replacement."

FDA product code: NPV

Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to regulations, other plan medical policies, and accredited national guidelines.

Transcatheter pulmonary valve implantation (TPVI) is a less invasive alternative to open surgical pulmonary valve replacement or reconstruction for right ventricular outflow tract (RVOT)

Transcatheter Pulmonary Valve Implantation

Policy # 00576

Original Effective Date: 10/18/2017

Current Effective Date: 10/01/2026

obstruction. Percutaneous pulmonary valve replacement may be indicated for congenital pulmonary stenosis. Pulmonary stenosis or regurgitation in a patient with congenital heart disease who has previously undergone RVOT surgery are additional indications. Patients with prior congenital heart disease repair are at risk of needing repeated reconstruction procedures.

Summary of Evidence

For individuals who have a history of congenital heart disease and current right ventricular outflow tract (RVOT) obstruction who receive transcatheter pulmonary valve implementation (TPVI) with a U.S. FDA approved device and indication, the evidence includes a systematic review of retrospective comparative studies, prospective, interventional, noncomparative studies, and a multicenter registry of 2476 individuals who underwent TPV replacement with a Melody (82%) or Sapien (18%) valve between July 2005 and March 2020. Relevant outcomes are overall survival, symptoms, functional outcomes, quality of life, hospitalizations, and treatment-related mortality and morbidity. Overall, the evidence suggests that TPVI is associated with high rates of short-term technical success and improvements in heart failure-related symptoms and hemodynamic parameters. Most valves have demonstrated competent functioning by Doppler echocardiography at 6- to 12-month follow-ups. Publications with longer follow-up have reported stent fractures in up to 26% of patients; however, most stent fractures did not require reintervention. Studies with follow-up extending to a maximum of 8 years post-procedure have suggested that the functional and hemodynamic improvements are durable. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have a history of congenital heart disease and current RVOT obstruction who receive TPVI with a non-FDA-approved device or indication, the evidence includes case series. Relevant outcomes are overall survival, symptoms, functional outcomes, quality of life, hospitalizations, and treatment-related mortality and morbidity. There is limited evidence on the off-label use of TPVI including the use of a non-FDA-approved valve or use of an approved valve for a non-FDA-approved indication. The published case series enrolled relatively few patients and are heterogeneous regarding devices used and indications for TPVI. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Supplemental Information

Clinical Input From Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

2018 Input

Clinical input was sought to help determine whether the use of transcatheter pulmonary valve implantation (TPVI) for individuals with congenital heart disease and current right ventricular outflow tract (RVOT) obstruction or regurgitation would provide a clinically meaningful improvement in the net health outcome and whether its use is consistent with generally accepted

Transcatheter Pulmonary Valve Implantation

Policy # 00576

Original Effective Date: 10/18/2017

Current Effective Date: 10/01/2026

medical practice. In response to requests, clinical input on the use of TPVI was received from 2 specialty society-level respondents while this policy was under review in 2018. The combined clinical input response incorporated input from a panel including physicians affiliated with academic medical centers.

Clinical input was provided by the following specialty societies:

- American College of Cardiology (ACC) and Society for Cardiovascular Angiography and Interventions (SCAI)^a

^a Indicates that conflicts of interest related to the topic where clinical input is being sought were identified by this respondent.

The clinical input supports that the following indications provide a clinically meaningful improvement in the net health outcome and are consistent with generally accepted medical practice:

- Use of TPVI for individuals with right ventricle-to-pulmonary artery conduit with or without bioprosthetic valve with at least moderate pulmonic regurgitation;
- Use of TPVI for individuals with native or patched RVOT with at least moderate pulmonic regurgitation;
- Use of TPVI for individuals with right ventricle-to-pulmonary artery conduit with or without bioprosthetic valve with pulmonic stenosis (mean RVOT gradient at least 35 mm Hg); or
- Use of TPVI for individuals with native or patched RVOT with pulmonic stenosis (mean RVOT gradient at least 35 mm Hg).

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American College of Cardiology, American Heart Association, et al

In 2025 the American College of Cardiology and American Heart Association and 6 other societies updated comprehensive guidelines on the management of patients with congenital heart disease. Included are recommendations for treatment of pulmonary stenosis, pulmonary regurgitation and tetralogy of Fallot (Table 2).

Table 2. ACC/AHA Guidelines on the Management of Patients with Tetralogy of Fallot

Recommendation	COR	LOE
"In symptomatic adults with moderate or severe valvular pulmonary stenosis who are ineligible for or have had suboptimal results after balloon valvuloplasty, pulmonary valve replacement is recommended to improve symptoms	1	B-NR

Transcatheter Pulmonary Valve Implantation

Policy # 00576

Original Effective Date: 10/18/2017

Current Effective Date: 10/01/2026

"In patients with symptomatic moderate or greater pulmonary regurgitation resulting from treated isolated valvular pulmonary stenosis, pulmonary valve replacement is recommended to improve symptoms"	1	B-NR
"In asymptomatic patients with moderate or greater pulmonary regurgitation resulting from treatment of isolated pulmonary stenosis with RV systolic dysfunction, pulmonary valve replacement is reasonable to restore valve function and preserve RV systolic function"	2a	C-LD
"In asymptomatic patients who have moderate or greater pulmonary regurgitation resulting from treatment of isolated pulmonary stenosis and at least moderate tricuspid regurgitation and/or progressive RV dilation or progressive decline in exercise capacity,* pulmonary valve replacement may be reasonable to restore valve function, ameliorate RV size, and preserve RV systolic function."	2b	C-LD
"In adults with repaired TOF and native RVOT anatomy being considered for transcatheter pulmonary valve replacement, cardiac CT is recommended to determine anatomic suitability"	1	B-NR
"In adults with repaired TOF with moderate or greater pulmonary valve dysfunction and progressive ventricular systolic dysfunction, pulmonary valve replacement (surgical or transcatheter) is reasonable to preserve ventricular function"	2a	C-LD
"In symptomatic adults with repaired TOF and moderate or greater pulmonary valve dysfunction,* pulmonary valve replacement (surgical or transcatheter) is recommended for relief of symptoms."	1	B-NR
"In asymptomatic adults with repaired TOF, moderate or greater pulmonary valve dysfunction,* and at least 2 of the following—RV end systolic volume index >80 mL/m ² , RV end-diastolic volume $\geq 2 \times$ LV end-diastolic volume, RV ejection fraction $\leq 46\%$, LV ejection fraction $\leq 50\%$, or progressive decline in exercise capacity—pulmonary valve replacement (surgical or transcatheter) is reasonable for improving outcomes, including lowering risks for ventricular arrhythmias and death"	2a	B-NR
In adults with repaired TOF and moderate or greater pulmonary regurgitation and ventricular tachyarrhythmia requiring treatment,‡ pulmonary valve replacement (surgical or percutaneous), in addition to electrophysiological intervention, may be considered."	2b	C-LD

ACC/AHA: American College of Cardiology/American Heart Association; B-NR: Non-randomized (moderate quality evidence); COR: class of recommendation; C-EO: consensus of expert opinion; LOE: level of evidence, PR: pulmonary regurgitation; TOF: tetralogy of Fallot

Transcatheter Pulmonary Valve Implantation

Policy # 00576

Original Effective Date: 10/18/2017

Current Effective Date: 10/01/2026

Society for Cardiovascular Angiography and Interventions and the Adult Congenital Heart Association

In 2020, the Society for Cardiovascular Angiography and Interventions and the Adult Congenital Heart Association published a position statement on operator and institutional recommendations for TPVI. Included were recommendations for interventional training, practicing physician competency, ongoing education and training, and institutional and team requirements.

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this review are listed in Table 3.

Table 3. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
<i>Ongoing</i>			
NCT02744677 ^a	Congenital Multicenter Trial of Pulmonic valve Dysfunction Studying the SAPIEN 3 interventional THV (COMPASSION S3)	108	Jun 2031
NCT02979587 ^a	The Medtronic Harmony™ Transcatheter Pulmonary Valve Clinical Study	86	Feb 2031
NCT04860765 ^a	Congenital Multicenter Trial of Pulmonic Valve Dysfunction Studying the SAPIEN 3 Interventional THV Post-Approval Study	150	Aug 2030
NCT05077774 ^a	Harmony TPV Post-Approval Study (Harmony PAS2)	150	Mar 2035
NCT06906926 ^a	Harmony TPV EMEA Post-Market Study	80	Dec 2032
<i>Unpublished</i>			
NCT02987387 ^a	New Enrollment SAPIEN XT Post-Approval Study (COMPASSION XT PAS)	57	Sep 2025

NCT: national clinical trial.

^a Denotes industry-sponsored or cosponsored trial.

Policy # 00576

Original Effective Date: 10/18/2017

Current Effective Date: 10/01/2026

References

1. Lopez KN, Baker-Smith C, Flores G, et al. Addressing Social Determinants of Health and Mitigating Health Disparities Across the Lifespan in Congenital Heart Disease: A Scientific Statement From the American Heart Association. *J Am Heart Assoc.* Apr 19 2022; 11(8): e025358. PMID 35389228
2. Khambadkone S, Nordmeyer J, Bonhoeffer P. Percutaneous implantation of the pulmonary and aortic valves: indications and limitations. *J Cardiovasc Med (Hagerstown).* Jan 2007; 8(1): 57-61. PMID 17255818
3. McElhinney DB, Hellenbrand WE, Zahn EM, et al. Short- and medium-term outcomes after transcatheter pulmonary valve placement in the expanded multicenter US melody valve trial. *Circulation.* Aug 03 2010; 122(5): 507-16. PMID 20644013
4. Ribeiro JM, Teixeira R, Lopes J, et al. Transcatheter Versus Surgical Pulmonary Valve Replacement: A Systemic Review and Meta-Analysis. *Ann Thorac Surg.* Nov 2020; 110(5): 1751-1761. PMID 32268142
5. Food and Drug Administration. Summary of Safety and Probable Benefit: Melody Transcatheter Pulmonary Valve and Ensemble Transcatheter Valve Delivery System. 2010; https://www.accessdata.fda.gov/cdrh_docs/pdf8/H080002b.pdf.
6. Zahn EM, Hellenbrand WE, Lock JE, et al. Implantation of the melody transcatheter pulmonary valve in patients with a dysfunctional right ventricular outflow tract conduit early results from the u.s. Clinical trial. *J Am Coll Cardiol.* Oct 27 2009; 54(18): 1722-9. PMID 19850214
7. Cheatham JP, Hellenbrand WE, Zahn EM, et al. Clinical and hemodynamic outcomes up to 7 years after transcatheter pulmonary valve replacement in the US melody valve investigational device exemption trial. *Circulation.* Jun 02 2015; 131(22): 1960-70. PMID 25944758
8. Batra AS, McElhinney DB, Wang W, et al. Cardiopulmonary exercise function among patients undergoing transcatheter pulmonary valve implantation in the US Melody valve investigational trial. *Am Heart J.* Feb 2012; 163(2): 280-7. PMID 22305848
9. Food and Drug Administration. Summary of Safety and Effectiveness Data (SSED): Edwards SAPIEN XT™ Transcatheter Heart Valve. 2016; https://www.accessdata.fda.gov/cdrh_docs/pdf13/p130009s037b.pdf.
10. Armstrong AK, Balzer DT, Cabalka AK, et al. One-year follow-up of the Melody transcatheter pulmonary valve multicenter post-approval study. *JACC Cardiovasc Interv.* Nov 2014; 7(11): 1254-62. PMID 25459038
11. Gillespie MJ, McElhinney DB, Kreutzer J, et al. Transcatheter Pulmonary Valve Replacement for Right Ventricular Outflow Tract Conduit Dysfunction After the Ross Procedure. *Ann Thorac Surg.* Sep 2015; 100(3): 996-1002; discussion 1002-3. PMID 26190388
12. Food and Drug Administration. Conditions for Approval for an HDE: Medtronic Melody Transcatheter Pulmonary Valve (Model PB 10) and Medtronic Ensemble Transcatheter Valve Delivery System (NU10) (H080002). 2010; https://www.accessdata.fda.gov/cdrh_docs/pdf8/H080002A.pdf.
13. Food and Drug Administration. Summary of Safety and Effectiveness Data: Melody™ Transcatheter Pulmonary Valve, models PB1016 and PB1018; Ensemble™ Transcatheter Valve Delivery System 2017; https://www.accessdata.fda.gov/cdrh_docs/pdf14/p140017s005b.pdf.

Transcatheter Pulmonary Valve Implantation

Policy # 00576

Original Effective Date: 10/18/2017

Current Effective Date: 10/01/2026

14. Jones TK, McElhinney DB, Vincent JA, et al. Long-Term Outcomes After Melody Transcatheter Pulmonary Valve Replacement in the US Investigational Device Exemption Trial. *Circ Cardiovasc Interv.* Jan 2022; 15(1): e010852. PMID 34930015
15. Georgiev S, Ewert P, Eicken A, et al. Munich Comparative Study: Prospective Long-Term Outcome of the Transcatheter Melody Valve Versus Surgical Pulmonary Bioprosthesis With Up to 12 Years of Follow-Up. *Circ Cardiovasc Interv.* Jul 2020; 13(7): e008963. PMID 32600110
16. Food and Drug Administration. Summary of Safety and Effectiveness Data (SSED): Edwards SAPIEN 3 Transcatheter Heart Valve System with Edwards Commander Delivery System. 2020; https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200015B.pdf.
17. Hainstock MR, Fleming G, Kim D, et al. Five-Year Outcomes for Patients With RVOT Dysfunction Treated With the SAPIEN 3 Transcatheter Heart Valve: A Pooled Analysis From the COMPASSION S3 Trial. *Circ Cardiovasc Interv.* May 2026; 19(5): e016361. PMID 41884901
18. Dimas VV, Babaliaros V, Kim D, et al. Multicenter Pivotal Study of the Alterra Adaptive Presept for the Treatment of Pulmonary Regurgitation. *JACC Cardiovasc Interv.* Oct 14 2024; 17(19): 2287-2297. PMID 39415386
19. Torres AJ, Dimas VV, Shahanavaz S, et al. Transcatheter Pulmonary Valve Implantation With the Alterra Adaptive Presept and SAPIEN 3 Transcatheter Heart Valve: 3-Year Pooled Outcomes of the ALTERRA Trials. *Circ Cardiovasc Interv.* Apr 2026; 19(4): e015873. PMID 41657206
20. Food and Drug Administration. Summary of Safety and Effectiveness: Harmony Transcatheter Pulmonary Valve. 2021. https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200046B.pdf
21. Gillespie MJ, Bergersen L, Benson LN, et al. 5-Year Outcomes From the Harmony Native Outflow Tract Early Feasibility Study. *JACC Cardiovasc Interv.* Apr 12 2021; 14(7): 816-817. PMID 33826508
22. Gillespie MJ, McElhinney DB, Jones TK, et al. 1-Year Outcomes in a Pooled Cohort of Harmony Transcatheter Pulmonary Valve Clinical Trial Participants. *JACC Cardiovasc Interv.* Aug 14 2023; 16(15): 1917-1928. PMID 37278682
23. McElhinney DB, Cabalka AK, Aboulhosn JA, et al. Transcatheter Tricuspid Valve-in-Valve Implantation for the Treatment of Dysfunctional Surgical Bioprosthetic Valves: An International, Multicenter Registry Study. *Circulation.* Apr 19 2016; 133(16): 1582-93. PMID 26994123
24. Boshoff DE, Cools BL, Heying R, et al. Off-label use of percutaneous pulmonary valved stents in the right ventricular outflow tract: time to rewrite the label?. *Catheter Cardiovasc Interv.* May 2013; 81(6): 987-95. PMID 22887796
25. Cheatham SL, Holzer RJ, Chisolm JL, et al. The Medtronic Melody® transcatheter pulmonary valve implanted at 24-mm diameter--it works. *Catheter Cardiovasc Interv.* Nov 01 2013; 82(5): 816-23. PMID 23359563
26. Veldurthy S, Shrivastava D, Majeed F, et al. Incidence of Infective Endocarditis Post-TPVR with MELODY Valve in Pediatric Patients: A Systematic Review and Meta-Analysis. *Curr Cardiol Rev.* 2025; 21(1): e1573403X324878. PMID 39289937
27. McElhinney DB, Zhang Y, Levi DS, et al. Reintervention and Survival After Transcatheter Pulmonary Valve Replacement. *J Am Coll Cardiol.* Jan 04 2022; 79(1): 18-32. PMID 34991785

Transcatheter Pulmonary Valve Implantation

Policy # 00576

Original Effective Date: 10/18/2017

Current Effective Date: 10/01/2026

28. McElhinney DB, Zhang Y, Aboulhosn JA, et al. Multicenter Study of Endocarditis After Transcatheter Pulmonary Valve Replacement. *J Am Coll Cardiol*. Aug 10 2021; 78(6): 575-589. PMID 34353535
29. McElhinney DB, Cheatham JP, Jones TK, et al. Stent fracture, valve dysfunction, and right ventricular outflow tract reintervention after transcatheter pulmonary valve implantation: patient-related and procedural risk factors in the US Melody Valve Trial. *Circ Cardiovasc Interv*. Dec 01 2011; 4(6): 602-14. PMID 22075927
30. Boudjemline Y, Malekzadeh-Milani S, Patel M, et al. Predictors and outcomes of right ventricular outflow tract conduit rupture during percutaneous pulmonary valve implantation: a multicentre study. *EuroIntervention*. Jan 22 2016; 11(9): 1053-62. PMID 25244126
31. Morray BH, McElhinney DB, Cheatham JP, et al. Risk of coronary artery compression among patients referred for transcatheter pulmonary valve implantation: a multicenter experience. *Circ Cardiovasc Interv*. Oct 01 2013; 6(5): 535-42. PMID 24065444
32. Fraisse A, Assaidi A, Mauri L, et al. Coronary artery compression during intention to treat right ventricle outflow with percutaneous pulmonary valve implantation: incidence, diagnosis, and outcome. *Catheter Cardiovasc Interv*. Jun 01 2014; 83(7): E260-8. PMID 24619978
33. Gurvitz M, Krieger EV, Fuller S, et al. 2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. Feb 24 2026; 87(7): 822-976. PMID 41411480
34. Aboulhosn JA, Hijazi ZM, Kavinsky CJ, et al. SCAI position statement on adult congenital cardiac interventional training, competencies and organizational recommendations. *Catheter Cardiovasc Interv*. Sep 01 2020; 96(3): 643-650. PMID 32272495

Policy History

Original Effective Date: 10/18/2017

Current Effective Date: 10/01/2026

10/05/2017	Medical Policy Committee review
10/18/2017	Medical Policy Implementation Committee approval. New policy.
08/09/2018	Medical Policy Committee review
08/15/2018	Medical Policy Implementation Committee approval. Clinical input was obtained and the first policy statement changed to: Transcatheter pulmonary valve implantation is considered medically necessary for patients with congenital heart disease and current right ventricular outflow tract obstruction or regurgitation including the specified indications.
01/01/2019	Coding update
08/01/2019	Medical Policy Committee review
08/14/2019	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/06/2020	Medical Policy Committee review
08/12/2020	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
09/02/2021	Medical Policy Committee review

Transcatheter Pulmonary Valve Implantation

Policy # 00576

Original Effective Date: 10/18/2017

Current Effective Date: 10/01/2026

09/08/2021	Medical Policy Implementation Committee approval. Policy statements minor revision to specify FDA-approved devices.
09/01/2022	Medical Policy Committee review
09/14/2022	Medical Policy Implementation Committee approval. No change to coverage.
09/07/2023	Medical Policy Committee review
09/13/2023	Medical Policy Implementation Committee approval. No change to coverage.
09/05/2024	Medical Policy Committee review
09/11/2024	Medical Policy Implementation Committee approval. No change to coverage.
09/04/2025	Medical Policy Committee review
09/10/2025	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
09/03/2026	Medical Policy Committee review
09/09/2026	Medical Policy Implementation Committee review
09/17/2026	Medical Quality Management Committee approval. Added “The use of transcatheter pulmonary valve implantation when patient selection criteria are not met is considered to be not medically necessary.” The following statement was changed from investigational to not medically necessary: “Based on review of available data, the Company considers transcatheter pulmonary valve implantation for all other indications to be not medically necessary.”

Next Scheduled Review Date: 09/2027

Coding

The five character codes included in the Louisiana Blue Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)†, copyright 2025 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Louisiana Blue Medical Policy Coverage Guidelines is with Louisiana Blue and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Louisiana Blue Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Louisiana Blue Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Transcatheter Pulmonary Valve Implantation

Policy # 00576

Original Effective Date: 10/18/2017

Current Effective Date: 10/01/2026

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	33477
HCPCS	No codes
ICD-10 Diagnosis	All related diagnoses

****Medically Necessary (or “Medical Necessity”)** - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

NOTICE: Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage.

NOTICE: If an authorization for an ongoing course of treatment has been provided to a member and the member changes from one health plan to another health plan (e.g., a member moves from carrier A to Louisiana Blue), Louisiana Blue may honor the previous health plan’s authorization for the same service under the same type of in-network benefit for a 90-day transition period. Documentation of the authorization for the ongoing course of treatment from the previous health

Transcatheter Pulmonary Valve Implantation

Policy # 00576

Original Effective Date: 10/18/2017

Current Effective Date: 10/01/2026

plan must be provided to us by the member or their provider and the services provided for the course of treatment must otherwise be a covered service under the Louisiana Blue health plan. This provision does not apply to medications covered under the plan's pharmacy benefit.